Blood Biomarkers to Improve Management of Children With Traumatic Brain Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

2880 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-02

Study Completion Date

2025-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Mild traumatic brain injury (TBI), defined by a Glasgow Coma Scale (GCS) score of 13 to 15, is the cause of many consultations in paediatric emergency departments (1), even though it is a rare cause of acute complication: approximately 10% of children present with intracranial lesions (ICL) on the CT scan and less than 1% require neurosurgical intervention (2). Although ICLs remain a serious complication requiring rapid diagnosis, brain CT scans, the gold standard diagnostic test, cannot be performed routinely because many children would be unnecessarily exposed to ionising radiation associated with an increased risk of cancer (3). In recent years, several clinical decision rules for the management of mTBI have therefore been developed with the aim of identifying children at high or very low risk of ICL in order to better target CT scan indications. Despite this, the rate of CT scans performed has remained high, up to 35%, and has not decreased with the application of these clinical decision rules (4).

Furthermore, even though the majority of children and adolescents recover quickly after mTBI, nearly 30% will present symptoms such as headaches, dizziness, asthenia, memory, concentration or sleep disorders persisting beyond one month with a possible impact on their quality of life (5). Thus, there is a need to develop new strategies to (i) limit the use of CT scans while minimising the risk of late diagnosis of ICL, (ii) identify children with a higher risk of adverse outcome and/or post-concussive symptoms.

One of the most promising strategies is the use of brain-based blood biomarkers. This study therefore aims to provide new knowledge on two of them, GFAP and UCH-L1 (6,7), in particular by using an automated test combining them (the VIDAS® TBI test developed by bioMérieux) in order to improve the management of CT in the paediatric population at the diagnostic and prognostic levels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

BLOOD BIOMARKERS in PAEDIATRIC MTBI

NCT06233851

Mild Traumatic Brain Injury

COMPLETED

Evaluation of Biomarkers of Traumatic Brain Injury

NCT01426919

Traumatic Brain Injury

COMPLETED

Management and Outcomes Following Emergency Surgery for Traumatic Brain Injury

NCT04212754

Traumatic Brain Injury Head Injury Brain Injuries +3 more

UNKNOWN

Vasospasm in Pediatric Traumatic Brain Injury

NCT01461902

Brain Injury

COMPLETED

Role of Concentration of Biomarkers S100B and NSE in Serum in Mild and Moderate Head Trauma

NCT02988102

Biomarkers

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Traumatic Brain Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biomarkers research

For a part of the included population, the children with a mTBI and without indication of CT scan, a non-routine blood sample will be planned

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Children and adolescents \<18 years old Consent from one of the parents of the child or from holder of parental responsibility Consent from the child or adolescent Parental affiliation with an appropriate health insurance system

1. TBI population

* Admission within 24 hours of the injury
* Ability to follow-up by telephone, mail or email
* For the mTBI group:

* GCS score of 13-15 on admission
* Indication for cerebral CT scan according to national or local guidelines or the in-charge physician OR diagnosis of concussion consistent with the fourth Zurich consensus statement (9) . Concussion was defined as a complex pathophysiological process caused by a direct blow to the head, face, neck, or elsewhere on the body with an impulsive force transmitted to the head (which may or may not have involved loss of consciousness), resulting in a brain injury with one or more symptoms in one or more of the following clinical domains: somatic, cognitive, emotional or behavioural, or sleep. To objectively help diagnose concussion, the validated Acute Concussion Evaluation (ACE) questionnaire (10) for children with mTBI will be used, the presence of ≥ 1 symptom on the ACE defines concussion.
* For the moderate or severe TBI group:

* GCS score of 3-12 on admission
* Indication for cerebral CT scan according to national or local guidelines or the in-charge physician
2. Non-TBI control paediatric population

* Admission for any reason other than TBI
* Indication of blood sampling for their routine management
* GCS score of 15
* Otherwise healthy, i.e. without chronic pathology

Exclusion Criteria

1. TBI population

* Time of injury unknown or exceeding 24 hours
* Blood sampling not possible within 24 hours after the injury or 6 hours after the CT scan, if applicable
* Penetrating brain injury with skull fracture
* Pre-existing neurological disorders affecting the assessment of neurological outcome, seizure disorder/epilepsy, brain tumour, history of neurosurgery, stroke, encephalopathy
* Venepuncture not feasible
* Pregnant woman
* Intoxication
* No clear primary mechanism of trauma
* No possibility for transferring CT scan images to the centralised platform in case of neuroimaging only performed in an outside hospital before transfer
* Participation in another interventional research study
2. Non-TBI control paediatric population

* Pre-existing neurological disorders, seizure disorder/epilepsy, brain tumour, history or indication of neurosurgery, stroke, encephalopathy
* History of TBI
* Orthopaedic trauma or surgery within the last month
* Suspected meningitidis or encephalitis
* Venepuncture not feasible
* Pregnant woman
* Intoxication
* Participation in another interventional research study

Minimum Eligible Age

0 Days

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fleur LORTON

Role: PRINCIPAL_INVESTIGATOR

Nantes University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.